[Therapeutic problems in disseminated encephalomyelitis (multiple sclerosis)].
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D004035:Diet Therapy; D004599:Electric Stimulation Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D000995:Antitubercular Agents; D005938:Glucocorticoids; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D014665:Vasodilator Agents; D014815:Vitamins
Therapeutische Probleme bei Encephalomyelitis disseminata (multipler Sklerose.